Investor Buys $81 Million in Praxis Stock as Shares Soar Over 300%

Baker Bros. Advisors LP significantly increased its stake in the biotech company as Praxis Precision Medicines advances late-stage CNS drug candidates.

Published on Feb. 23, 2026

Got story updates? Submit your updates here. ›

Baker Bros. Advisors LP, a prominent investment firm, disclosed the purchase of 437,000 shares of Praxis Precision Medicines (NASDAQ:PRAX) in the fourth quarter of 2025, valued at an estimated $81.38 million. This transaction increased the fund's total stake in Praxis to 1,126,488 shares, now worth $332.02 million due to the stock's over 300% surge in the past year.

Why it matters

Praxis Precision Medicines is a Boston-based biotech company focused on developing therapies for neurological and psychiatric disorders. The significant investment by Baker Bros. Advisors, a respected healthcare-focused fund, signals confidence in Praxis' pipeline of late-stage CNS drug candidates and their potential to capture a sizable share of the multibillion-dollar market.

The details

According to the SEC filing, Baker Bros. Advisors increased its stake in Praxis Precision Medicines by 437,000 shares during Q4 2025, with the estimated transaction value of $81.38 million based on the quarter's average closing price. This move expanded the fund's total position to 1,126,488 shares, now valued at $332.02 million. Praxis is advancing a robust pipeline of differentiated CNS therapies, including two New Drug Applications (NDAs) submitted in early 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies. The company believes its late-stage assets represent over $20 billion in potential revenue.

  • On February 17, 2026, Baker Bros. Advisors LP disclosed the purchase of 437,000 Praxis Precision Medicines shares.
  • Praxis submitted two NDAs in early 2026 for ulixacaltamide and relutrigine.

The players

Baker Bros. Advisors LP

A prominent investment firm focused on the healthcare sector that significantly increased its stake in Praxis Precision Medicines.

Praxis Precision Medicines

A Boston-based biotechnology company focused on advancing therapies for neurological and psychiatric disorders with significant unmet medical need.

Got photos? Submit your photos here. ›

The takeaway

While Praxis Precision Medicines has seen a remarkable stock surge of over 300% in the past year, the significant investment by Baker Bros. Advisors suggests the biotech firm's pipeline of CNS drug candidates may have substantial long-term potential. However, investors should carefully consider the Motley Fool's cautionary note and evaluate Praxis' regulatory timelines, launch execution, and upcoming clinical data before making investment decisions.